Tackle small molecule drug discovery screening challenges with Dianthus

A big hurdle in small molecule drug discovery screening is confidently identifying positive hits in a timely manner. Screening fragment libraries is challenging with current methodologies that are either time-consuming or lack detection sensitivity. Dianthus NT.23PicoDuo utilizes a biophysical detection method for fast, precise and confident hit identification, target validation and lead optimization. An example of single-dose and affinity screening against histone methylase G9a, known to be associated with cancer onset, will be discussed.

Previous Video
Measuring stability to more effectively select therapeutic antibody candidates
Measuring stability to more effectively select therapeutic antibody candidates

This therapeutic antibody drug development webinar discusses the idea of limiting the substantial investmen...

Up next
Overcome challenges in vaccine development with deeper antigen stability characterization
Overcome challenges in vaccine development with deeper antigen stability characterization

Vaccines are biological products derived from living organisms that provide an immune response to pathogen...

×

Sign up to receive
the latest NanoTemper news, product updates, event announcements and more

First Name
Last Name
Company Name
Country
State
Province
State
Region
State
Canton
Agree to Subscribe & Privacy Policy*
*I have fully read, understood and agree to the Privacy Policy. I accept the storing and processing of my personal data by NanoTemper as described in the Privacy Policy.

By completing this form, you provide us consent to contact you with educational content, news and information about our products, services and events. You may unsubscribe at any time.
Thank you!
Error - something went wrong!